Prosecution
BSKB has been preparing and prosecuting patent applications for our clients since 1976. Our attorneys have substantial experience in preparing and prosecuting patent applications as well as providing validity and infringement opinions, portfolio management and client counseling in the area of chemistry/biotech, electronics/information technology, and mechanical engineering. Our clients include major manufacturers in a variety of industries, research organizations and universities.
Our reputation in this field is directly attributable to the level of skill among our attorneys and patent agents. A number of our attorneys and agents have worked for corporations, research institutes or the government and have been actively involved in all phases of product development. Many are also former examiners at the U.S. Patent and Trademark Office and have first-hand knowledge of and insight into the procedures and prosecution strategies that help our clients obtain the broadest range of protection efficiently.
BSKB has consistently ranked among the top patent firms in the U.S. for number of patent registrations annually. Our attorneys and agents participate in various domestic and international intellectual property organizations and regularly lecture to groups in the U.S. and abroad. BSKB attorneys and agents are also involved in a number of technical and legal organizations and attend meetings to stay current on the technological and legal advancements in their fields.
Attorneys and Professionals
Insights
-
December 26, 2022
Key U.S. Supreme Court Developments in 2022 and Outlook for 2023
IPWatchdog
As the 2022 year comes to an end, Dr. Hailey Bureau reflects on the Intellectual Property industry and the key SCOTUS decisions of 2022 that impacted patent and trademark law.
-
July 1, 2022
"Pharma Patents Under Fire From Federal Circuit, Petitions Say"
Bloomberg Law
BSKB's Hailey R. Bureau, Ph.D., was quoted in an article for Bloomberg Law regarding recent rulings by the US Court of Appeals for the Federal Circuit regarding strict enforcement of certain Patent Act provisions. These rulings regarding Section 112(a), a written description requirement and an enablement standard, have created a high burden for Applicants in the life science industry to overcome.
Related Presentations
-
May 24, 2023
UCB v. Actavis Laboratories – Relying on range limitations in claims to distinguish from prior art
-
May 10, 2023
Discussion of 35 U.S.C. § 103 Rejections and “Known Technique” Rationale
-
March 29, 2023
Can an Article of Manufacture be an Abstract Idea?
-
March 8, 2023
Duty of Disclosure and Duty of Reasonable Inquiry
Recent News
-
February 27, 2023
USPTO ANNOUNCEMENT
The electronic patent grant will be the official statutory patent grant effective April 18, 2023.
-
December 29, 2022
USPTO DOCX ANNOUNCEMENT
The U.S. Patent and Trademark Office (USPTO) has delayed the implementation of the non-DOCX filing surcharge until April 3, 2023.